Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Praxis Precision Medicines | 2026 | Post Ipo Equity | $575.0M | Cambridge |
| Mirum Pharmaceuticals | 2025 | Post Ipo Equity | $68.5M | Foster City |
| The Protein Brewery | 2025 | Grant | $2.7M | Breda |
| Sidera Bio | 2025 | Series A | $109.0M | Copenhagen |
| Chromologics | 2025 | Series Unknown | $8.1M | Søborg |
| Booster Therapeutics | 2025 | Grant | $5.0M | Berlin |
| Cogent Biosciences | 2025 | Post Ipo Debt | $200.0M | Waltham |
| EnergyRe | 2025 | Debt Financing | $370.0M | New York |
| Hemab | 2025 | Series C | $157.0M | Copenhagen |
| MATR Foods | 2025 | Series A | $23.2M | Copenhagen |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 51 | Praxis Precision Medicines | Post Ipo Equity | $575.0M | Cambridge, United States |
| 52 | Mirum Pharmaceuticals | Post Ipo Equity | $68.5M | Foster City, United States |
| 53 | The Protein Brewery | Grant | $2.7M | Breda, The Netherlands |
| 54 | Sidera Bio | Series A | $109.0M | Copenhagen, Denmark |
| 55 | Chromologics | Series Unknown | $8.1M | Søborg, Denmark |
| 56 | Booster Therapeutics | Grant | $5.0M | Berlin, Germany |
| 57 | Cogent Biosciences | Post Ipo Debt | $200.0M | Waltham, United States |
| 58 | EnergyRe | Debt Financing | $370.0M | New York, United States |
| 59 | Hemab | Series C | $157.0M | Copenhagen, Denmark |
| 60 | MATR Foods | Series A | $23.2M | Copenhagen, Denmark |
Praxis develops therapies for CNS disorders by leveraging genetic insights into neuronal imbalances, targeting rare to common conditions.
Mirum Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of therapies.
The Protein Brewery specializes in developing and making animal-free-based protein in a sustainable way.
Sidera Bio harness human genetics, that helps in transformative medicines for patients.
Chromologics develops innovative natural food colorants.
Booster Therapeutics is a biotech company that offers regulation of cellular homeostasis, as well as develops medicines for aging diseases.
Cogent Biosciences is a biotechnology company that develops therapies for solid cancer tumors.
EnergyRe is at the center of the clean energy future.
Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
MATR Foods is a food-tech startup that provides fungi-based food ingredients.
Cleveland Diagnostics is a diagnostics company developing efficacious, affordable diagnostics tests to improve cancer diagnostics.
LEXEO Therapeutics utilizes gene therapy to treat genetically defined cardiovascular and central nervous system diseases.
Expedition Therapeutics is a biotechnology company that develops novel therapies for inflammatory and respiratory diseases.
Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.
KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
Nalu Medical is a medical technology company that offers neurostimulation system designed to treat chronic nerve pain.
Phasecraft develops quantum algorithms and related intellectual property for scientific and industrial applications.
BBOT is a clinical-stage biopharmaceutical company advancing a pipeline of novel therapeutics targeting RAS and PI3Kα malignancies.
Mission Bio develops only single-cell multi-omics platform integrating genotype and phenotype for cancer research and biomarker development.
MapLight Therapeutics is a biopharma company that offers a platform designed to discover and develop therapeutics for brain disorders.
MedGenome develops a genomics-based diagnostics and research solution for healthcare providers to understand the genetic basis of diseases.
Tempus develops AI-enabled precision medicine technology that supports clinical decision-making and biomedical research.
Based on our deep science and focused on patients in need.
GlycoEra is a biotechnology research company that produces extracellular protein degraders for the treatment of autoimmune diseases.
Ray Therapeutics is a biotech company that develops optogenetic gene therapies for patients with blinding diseases.
Novo Holdings has invested in 154 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Novo Holdings's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 30 different industry categories.
Among tracked funding rounds, Tempus received $650.0M in a Post Ipo Debt round. Novo Holdings's total known invested capital is $9.7B.
Novo Holdings's average investment size is $85.4M across its portfolio of 154 companies.
Recent Novo Holdings portfolio additions include Praxis Precision Medicines, Mirum Pharmaceuticals, The Protein Brewery, Sidera Bio, Chromologics. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors